Hypereosinophilia during dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps
Rhinology Journal · 01.11.2023 · 0-0
DOI: 10.4193/rhin23.357 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Rhinology Journal, online erschienen am 01.11.2023. Verfasst von P Kemp und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Nasal Polyps, Rhinosinusitis, Rhinitis, Sinusitis. Die Arbeit wurde bisher 11-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND: Increased blood eosinophil count (BEC) is common in patients under dupilumab treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). This study investigated the prevalence and consequences of hypereosinophilia and to help define patients at risk. METHODS: Real-life, prospective observational cohort study of patients treated with dupilumab for severe CRSwNP. Eligible patients were adult and biological-naïve (N=334). All BEC values at baseline and during treatment were reported. Patients with a follow-up of ≥ 1 year were included to define patients at risk for hypereosinophilia by comparing baseline BEC values (N=218). Furthermore, clinical characteristics and therapeutic consequences for patients with BEC ≥ 3.0 were noted. RESULTS: Hypereosinophilia developed in a minority of patients, with a peak at week 12 (16.2% with BEC ≥ 1.5, and 1.7% ≥ 3.0) in cross-sectional analysis. BEC ≥ 1.5 developed in 28.9% and BEC ≥ 3.0 in 4.6% of cases with a minimal 1-year follow-up. Baseline BEC was significantly higher for patients developing BEC ≥ 1.5 and BEC ≥3.0, with an optimal cut-off point of 0.96 to predict developing BEC ≥ 3.0. CONCLUSIONS: Blood eosinophil count (BEC) ≥ 1.5 is transient and usually abates with no therapeutic interventions and BEC ≥ 3.0 is rare. Hypereosinophilic syndrome did not occur and switching to a different biological was rarely employed. A baseline BEC of ≥1.0 can be a reason for extra caution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
- Department of Otorhinolaryngology, Alrijne Hospital, Leiden, The Netherlands.
- Department of Otorhinolaryngology, Isala Hospital, Zwolle, The Netherlands.
- Department of Otorhinolaryngology, GZA Hospital Sint-Vincentius, Antwerp, Belgium.
Zitieren
APA
Kemp, P., van der Lans, R. J. L., Otten, J. J., Adriaensen, G. F. J. P. M., Benoist, L. B. L., Cornet, M. E., Hoven, D. R., Rinia, B., Verkest, V., Fokkens, W. J., & Reitsma, S. (2023). Hypereosinophilia during dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps. Rhinology Journal, 0(0), 0-0. https://doi.org/10.4193/rhin23.357
Vancouver
Kemp P, van der Lans RJL, Otten JJ, Adriaensen GFJPM, Benoist LBL, Cornet ME, et al. Hypereosinophilia during dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps. Rhinology Journal. 2023;0(0):0-0. doi:10.4193/rhin23.357
BibTeX
@article{Kemp2023,
author = {Kemp, P and van der Lans, R J L and Otten, J J and Adriaensen, G F J P M and Benoist, L B L and Cornet, M E and Hoven, D R and Rinia, B and Verkest, V and Fokkens, W J and Reitsma, S},
title = {Hypereosinophilia during dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps},
journal = {Rhinology Journal},
year = {2023},
volume = {0},
number = {0},
pages = {0--0},
doi = {10.4193/rhin23.357}
}
EUVIMED